Presentation at J.P. Morgan H

RNS Number : 5278Y

Oxford Biomedica PLC

23 December 2010

 



OXFORD BIOMEDICA TO PRESENT AT J.P. MORGAN 29^TH

ANNUAL HEALTHCARE CONFERENCE

Oxford, UK - 23 December 2010: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica, will present at the J.P. Morgan 29^th Annual Healthcare Conference in San Francisco, California on Thursday, 13 January 2011 at 10:00 PST/18:00 GMT.

A copy of the presentation will be available from the investor relations section of the Company's website, www.oxfordbiomedica.co.uk.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Media/Financial Enquiries: Emma Thompson/Amber Bielecka/Rob Newman M:Communications	Tel: [phone]
US Enquiries: Simon Harnest The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer.  Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

NRAEAFADASKEFFF